Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · Real-Time Price · USD

7.34

+0.20 (2.80%)

At close: Sep 26, 2025, 4:00 PM EDT

7.28

-0.06 (-0.81%)

After-hours: Sep 26, 2025, 7:46 PM EDT

Sagimet Biosciences Employees

Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.

Employees

14

Change (1Y)

4

Growth (1Y)

40.00%

Revenue / Employee

n/a

Profits / Employee

-$4,241,571

Market Cap

238.71M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	4	40.00%
Dec 31, 2023	10	0	-
Dec 31, 2022	10	3	42.86%
Dec 31, 2020	7	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

SGMT News

10 days ago - Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis - GlobeNewsWire
17 days ago - Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - GlobeNewsWire
20 days ago - Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
4 weeks ago - Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development - Seeking Alpha
4 weeks ago - Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
6 weeks ago - Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
7 weeks ago - Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
3 months ago - Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - GlobeNewsWire